2.01 (-%)
As of Nov 20, 2024
Source:
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.
Country | United States |
Headquarters | dallas, texas |
Phone Number | ( 214 ) 612-0000 |
Industry | manufacturing |
CEO | Sean Nolan |
Website | www.tayshagtx.com |